While the symptom-triggered regimen was associated with a reduction in the dose and duration of lorazepam use, it was important to examine whether treatment reduction was associated with a change in safety and withdrawal intensity.Table 4 shows that in spite of receiving less drug for a significantly shorter duration of time, the study subjects in the STR
did not develop significantly higher rates of adverse events.